PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1616710
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1616710
Atrial Fibrillation Devices Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
The Global Atrial Fibrillation Devices Market was valued at USD 10.6 billion in 2023 and is projected to grow at a CAGR of 11.5% from 2024 to 2032. This robust growth is primarily driven by advancements in atrial fibrillation devices, a rising prevalence of AF, an increasing adoption of cardiac ablation procedures, and heightened awareness leading to early diagnosis. The incidence of atrial fibrillation is on the rise globally, making it the most common type of cardiac arrhythmia. Contributing factors include aging populations and increasing rates of obesity, hypertension, and other cardiovascular conditions. With millions affected worldwide, the demand for both diagnostic and treatment devices is escalating.
Increased awareness about atrial fibrillation among patients and healthcare providers has led to more timely diagnoses and treatment. Public health initiatives and educational campaigns highlight the importance of monitoring and managing AF, boosting demand for AF devices. Early detection is crucial to preventing complications like stroke, which in turn drives the use of diagnostic and monitoring tools. Atrial fibrillation devices are essential medical tools used to diagnose, monitor, and treat AFib, a common heart rhythm disorder.
These include catheters for defibrillators implantable cardiac monitors, ablation procedures, and pacemakers that help regulate heart rhythm. Their main goals are to restore normal heart function, prevent strokes, and alleviate AFib-related symptoms. These devices play a vital role in both the acute and long-term management of AFib patients. The market is segmented by product, including cardiac monitors, EP ablation catheters, mapping systems, EP diagnostic catheters, access devices, left atrial appendage closure devices, intracardiac echocardiography (ICE), and other related products.
| Market Scope | |
|---|---|
| Start Year | 2023 |
| Forecast Year | 2024-2032 |
| Start Value | $10.6 Billion |
| Forecast Value | $27.9 Billion |
| CAGR | 11.5% |
The EP ablation catheters segment garnered the highest revenue, driven by technological advancements that enhance safety and efficacy in ablation procedures. Innovations in catheter design and improved energy delivery systems have expanded the range of patients who can benefit from ablation, further propelling market growth. In terms of end-use, the atrial fibrillation devices market is divided into ambulatory surgical centers, hospitals, cardiac centers, and others. The hospitals segment led the market in 2023, fueled by the increasing need for specialized treatment centers that require a variety of AF devices for diagnosis, treatment, and patient monitoring.
The North America atrial fibrillation devices market amassed USD 4.3 billion in revenue in 2023 and is expected to grow at a CAGR of 11.3% from 2024 to 2032. This region's high prevalence of AF is influenced by an aging population and a rise in lifestyle-related conditions. High healthcare expenditure in North America supports significant investments in advanced medical technologies, including atrial fibrillation devices, stimulating market growth.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 High adoption rate of advanced technologies and presence of sophisticated healthcare infrastructure
- 3.2.1.2 Increase in prevalence of cardiovascular diseases
- 3.2.1.3 Rising geriatric population
- 3.2.1.4 Rise in prevalence of rheumatic valvular heart diseases
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 High cost associated with atrial fibrillation devices
- 3.2.2.2 Lack of awareness regarding enhanced medical technologies in developing countries
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Technology landscape
- 3.6 Reimbursement scenario
- 3.7 Atrial fibrillation catheter ablation procedures at global and regional level, 2021 - 2023
- 3.7.1 Global
- 3.7.2 North America
- 3.7.3 Europe
- 3.7.4 Asia Pacific
- 3.7.5 Latin America
- 3.7.6 Middle East & Africa
- 3.8 Catheter ablation centres, by region, 2021 - 2023
- 3.9 Atrial fibrillation devices market, 2021 -2032 (Units)
- 3.9.1 Global
- 3.9.2 North America
- 3.9.3 Europe
- 3.9.4 Asia Pacific
- 3.9.5 Latin America
- 3.9.6 MEA
- 3.10 Pricing analysis
- 3.11 Gap analysis
- 3.12 Porter's analysis
- 3.13 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Company market share analysis
- 4.4 Competitive positioning matrix
- 4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 EP ablation catheters
- 5.2.1 Radiofrequency (RF)
- 5.2.2 Laser
- 5.2.3 Cryoablation
- 5.2.4 Ultrasound
- 5.2.5 Microwave
- 5.2.6 Other EP ablation catheters
- 5.3 Cardiac monitors or implantable loop recorder
- 5.4 EP diagnostic catheters
- 5.4.1 Advanced mapping catheters
- 5.4.2 Steerable catheters
- 5.4.3 Fixed curve catheters
- 5.5 Mapping and recording systems
- 5.6 Access devices
- 5.7 Intracardiac echocardiography (ICE)
- 5.8 Left atrial appendage (LAA) closure devices
- 5.9 Other products
Chapter 6 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Hospitals
- 6.3 Cardiac centers
- 6.4 Ambulatory surgical centers
- 6.5 Other end-users
Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
- 7.3 Europe
- 7.3.1 Germany
- 7.3.2 UK
- 7.3.3 France
- 7.3.4 Spain
- 7.3.5 Italy
- 7.3.6 Netherlands
- 7.3.7 Rest of Europe
- 7.4 Asia Pacific
- 7.4.1 Japan
- 7.4.2 China
- 7.4.3 India
- 7.4.4 Australia
- 7.4.5 South Korea
- 7.4.6 Rest of Asia Pacific
- 7.5 Latin America
- 7.5.1 Brazil
- 7.5.2 Mexico
- 7.5.3 Argentina
- 7.5.4 Rest of Latin America
- 7.6 Middle East and Africa
- 7.6.1 South Africa
- 7.6.2 Saudi Arabia
- 7.6.3 UAE
- 7.6.4 Rest of Middle East and Africa
Chapter 8 Company Profiles
- 8.1 Abbott Laboratories
- 8.2 Acutus Medical, Inc.
- 8.3 AtriCure, Inc.
- 8.4 Biotronik
- 8.5 Boston Scientific Corporation
- 8.6 CardioFocus
- 8.7 CathRx Ltd.
- 8.8 Hansen Medical, Inc.
- 8.9 Imricor
- 8.10 Johnson and Johnson (Biosense Webster)
- 8.11 Medtronic plc
- 8.12 MicroPort Scientific Corporation
- 8.13 OSYPKA MEDICAL
- 8.14 Stryker Corporation
- 8.15 Synaptic Medical
